Ruppé Etienne, Cherkaoui Abdessalam, Lazarevic Vladimir, Emonet Stéphane, Schrenzel Jacques
Genomic Research Laboratory, Geneva University Hospitals, CMU-9F, Rue Michel Servet 1, CH-1211 Geneva 14, Switzerland.
Laboratory of Bacteriology, University Hospitals, Rue Gabrielle Perret-Gentil 4, CH-1211 Geneva 14, Switzerland.
Antibiotics (Basel). 2017 Nov 29;6(4):30. doi: 10.3390/antibiotics6040030.
Clinical metagenomics (CMg), referred to as the application of next-generation sequencing (NGS) to clinical samples, is a promising tool for the diagnosis of hospital-acquired pneumonia (HAP). Indeed, CMg allows identifying pathogens and antibiotic resistance genes (ARGs), thereby providing the information required for the optimization of the antibiotic regimen. Hence, provided that CMg would be faster than conventional culture, the probabilistic regimen used in HAP could be tailored faster, which should lead to an expected decrease of mortality and morbidity. While the inference of the antibiotic susceptibility testing from metagenomic or even genomic data is challenging, a limited number of antibiotics are used in the probabilistic regimen of HAP (namely beta-lactams, aminoglycosides, fluoroquinolones, glycopeptides and oxazolidinones). Accordingly, based on the perspective of applying CMg to the early diagnostic of HAP, we aimed at reviewing the performances of whole genomic sequencing (WGS) of the main HAP-causing bacteria (Enterobacteriaceae, , , and ) for the prediction of susceptibility to the antibiotic families advocated in the probabilistic regimen of HAP.
临床宏基因组学(CMg),即下一代测序(NGS)在临床样本中的应用,是诊断医院获得性肺炎(HAP)的一种很有前景的工具。事实上,CMg能够识别病原体和抗生素耐药基因(ARG),从而为优化抗生素治疗方案提供所需信息。因此,如果CMg比传统培养更快,那么HAP中使用的经验性治疗方案就能更快地调整,这有望降低死亡率和发病率。虽然从宏基因组甚至基因组数据推断抗生素敏感性测试具有挑战性,但HAP经验性治疗方案中使用的抗生素种类有限(即β-内酰胺类、氨基糖苷类、氟喹诺酮类、糖肽类和恶唑烷酮类)。因此,基于将CMg应用于HAP早期诊断的角度,我们旨在综述主要HAP致病菌(肠杆菌科、 、 、 和 )的全基因组测序(WGS)在预测HAP经验性治疗方案中所倡导的抗生素家族敏感性方面的性能。